Abstract: Rheumatoid arthritis is a chronic inflammatory disease, leading to joint destruction. Conventional therapy is based on pain-reduction and an improvement in the frictional properties of joints, in order to delay the time for operative intervention. A lack of specifically-acting agents for drug-based therapy for arthritis exists. The formulations comprise sulphated hyaluronic acids with varying degrees of sulphation, or the pharmacologically acceptable salts thereof and, optionally, hyaluronic acid and/or hyaluronic acid uronide. The pharmaceutical formulations are highly concentrated injection preparations with an aqueous, viscous, gel-like, or paste-like form, or a low-concentration rinsing fluid for intra-articular application.

Abstract: The invention relates to methods for individually separating microorganisms from a suspension or culture, parallel cultivation of individual cells and analyzing the metabolic performances thereof. The invention enables basic microbial operations such as media optimization, screening according to images of novel natural substances and special metabolic performances, qualitative and quantitative detection of the effects of nutrient substrates, effectors and active substances including the media optimization and selection of microorganism clones with specific properties from large populations according to mutagenesis, transformation, transfection and genetic processing in addition to the detection of microbial contaminations to be carried out.

Abstract: The invention relates to an agent for treating skin diseases and/or functional disorders of the skin on the basis of different medicaments and/or auxiliary substances through promotion of penetration from topical formulations into the skin. According to the invention, the agent is composed of a hyaluronate lyase produced by microbial means and a medicament, preferably a hydrophilic medicament and/or auxiliary substances in different galenic formulations including colloidal carrier systems. The areas of application for the invention in human and veterinary medicament relate to the treatment, prophylaxis and/or metaphylaxis of skin diseases, functional disorders of the skin, the processes of skin ageing and dry skin conditions.

Abstract: Rheumatoid arthritis is a chronic inflammatory disease, leading to joint destruction. Conventional therapy is based on pain-reduction and an improvement in the frictional properties of joints, in order to delay the time for operative intervention. A lack of specifically-acting agents for drug-based therapy for arthritis exists. The formulations comprise sulphated hyaluronic acids with varying degrees of sulphation, or the pharmacologically acceptable salts thereof and, optionally, hyaluronic acid and/or hyaluronic acid uronide. The pharmaceutical formulations are highly concentrated injection preparations with an aqueous, viscous, gel-like, or paste-like form, or a low-concentration rinsing fluid for intra-articular application.

Abstract: The invention relates to an agent for the treatment, prophylaxis and metaphylaxis of functional and structural disorders of the skin caused by external factors. The agent contains a hyaluronic acid partially digested with a microbiological hyaluronate lyase. The hyaluronic acid fragment mixture is incorporated in different galenic formulations to which other hydrophilic and/or lipophilic active substances and/or auxiliary substances can be added. Fields of application of the invention in human and veterinary medicine relate to the treatment and/or the prophylaxis of skin damage caused by environmental factors including UV, dry skin conditions and skin ageing.